No Data
No Data
Express News | Sarepta Therapeutics Inc - Anticipates Filing for Accelerated Approval of Srp-9003 in 2025
Express News | Sarepta Therapeutics Completes Enrollment in Emergene, a Phase 3 Clinical Study of Srp-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing
Insider Sale: Director at $SRPT (SRPT) Sells 10,500 Shares
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
Unlock the Full List